ATLANTA--(www.irrisept.com), the only FDA-cleared cleansing and debridement system containing 0.05% chlorhexidine gluconate (CHG) for the cleansing and irrigation of wounds, has named medical device and pharmaceutical clinical leadership veteran Carolyn Twomey, RN, BSN, as the company’s first vice president, clinical affairs.)--IrriMax® Corporation, developer of IrriSept® (
“I was compelled to join IrriMax after learning about the benefits of IrriSept”
“Having Carolyn, a well-respected industry expert, spearhead our clinical efforts is a major milestone for IrriMax and a significant endorsement of our technology,” says Chief Executive Officer Gareth Clarke. “Her passion about IrriSept – and its potential to improve patient outcomes and help reduce healthcare-associated infections (HAIs) and their related costs – makes her an ideal member of our leadership team.”
Twomey’s primary responsibility is to establish clinical strategy for the medical device company’s flagship products, IrriSept and IrriSept O.R. She will work directly with leading clinical researchers to design clinical trials and is also charged with assuring clinical program accuracy, creating accredited continuing education programs, providing clinical support for field sales personnel and forming a clinical advisory council.
“I was compelled to join IrriMax after learning about the benefits of IrriSept,” explains Twomey. “It’s an important innovation that I believe can help address some of today’s most critical healthcare issues: surgical site infections, healthcare-associated infections, and skin and soft tissue infections.”
Twomey has more than three decades of experience as a clinician, executive manager and clinical consultant. Prior to joining IrriMax, she was chief clinical officer for Microdermis Corporation and president of Pivotal Clinical Solutions. During her tenure at Molnlycke Health Care she served as global head of clinical services for global surgical gloves business unit, as well as in various clinical leadership positions in the U.S. division. Early in her career, Twomey excelled as a perioperative nurse, critical care nurse manager and director of interventional cardiology. She also served as assistant professor of surgery of the division of general and trauma surgery, and director of the Advanced Life Support Center at the Medical College of Virginia.
Currently Twomey serves as trustee, AORN Foundation Board. She is also a member of Association of Professionals in Infection Control, Infectious Disease Society of America, Society of Clinical Research Associates and is an associate member of American College of Surgeons.
Twomey has published articles in Journal of the American College of Surgeons, AORN Journal, Joint Commission Journal on Quality and Safety, Infection Control Today, Managing Infection Control and Surgical Products. She frequently speaks at global and U.S. conferences including Association of Operating Room Nurses Congress, European Operating Room Nurses Congress, ANA Magnate Conference, Ambulatory Surgery Conference, Japanese Operating Room Nurses Congress, Korean Association of Operating Room Nurses and Australian College of Operating Room Nurses. Twomey received her degree in nursing from Mississippi College.
About IrriMax Corporation
Founded in 2003, IrriMax® Corporation is a medical device company whose corporate goals are focused on treating and preventing infections, reducing healthcare costs, improving patient outcomes and increasing the safety of healthcare professionals. Continual innovation and ongoing clinical research guide the development of IrriMax products. For more information, visit www.irrisept.com.